Case Number 6086
Request Date 13/06/2018
Completion Date 02/07/2018

 

Details of the Request

1 - In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018 ?

2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources ? If yes, please provide details

3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018 ?

4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made ? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products)

If “Yes”, then please provide the following details:

  • Name of specific drugs involved
  • Disease Area
  • CCG(s) included in the Gainshare agreement
  • Savings apportioned between Provider and the CCG(s)
  1. Infliximab
  2. Etanercept
  3. Rituximab
  4. Adalimumab
  5. Trastuzumab

 

5 – Are there any other agreements with a CCG, not included in the above, for the following services ?

If “Yes”, then please provide the following details:

  • Disease Area
  • CCG(s) included in the agreement
  • Name of specific drugs involved
  • Type of agreement with the Provider
  1. Ophthalmology services (eg wet macular degeneration)
  2. Multiple Sclerosis
  3. Prostate Cancer
  4. Breast Cancer
  5. Haemophilia

 

Details of the Response

1) In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018 ?

£7,918,855.43

 

2) Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources ?

The Trust has no local policy but each switch is project managed. Our Drugs and Therapeutics Committee are made aware of switch plans in advance. Switches are planned with the local commissioners and our local CCGs formalise prescribing pathways and policies to include biosimilars. These are available in the public domain via the Surrey PAD. The Regional Medicines Optimisation Committee Briefings cascaded via Specialist Pharmacy Services are referred to during the process.

 

3) Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018 ?

Yes, we created a plan with engagement from local clinicians and our local CCG, to agree a process and timescales for the project.

 

4) Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made ?

No

 

5) Are there any other agreements with a CCG, not included in the above, for the following services?

No

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.